Logo for the company Immunogen X, green and blue geometric shapes

News & Press Release

  • Press Releases
  • News
ImmunogenX Delivers Invited Talk at International Symposium
May 6, 2023
ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology
August 12, 2022
ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference
May 17, 2022
ImmunogenX to Make Highlighted Presentations at DDW 2022
February 23, 2022
ImmunogenX to Make Highlighted Presentations at DDW 2017
February 23, 2022
ImmunogenX and Mayo Clinic Successfully Complete the CeliacShield Trial
March 18, 2021
ImmunogenX Receives a Tibbetts Award
February 18, 2021
ImmunogenX Publishes in Celiac Disease Journal
August 11, 2020
ImmunogenX and Mayo Clinic CeliacShield Trial for Latiglutenase Passes Safety and Efficacy Midterm Assessment
July 2, 2020
Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease
February 13, 2020
Further Latiglutenase Analyses Published in GastroHep
December 10, 2019
National Institutes of Health (NIH) Awards Another Major Grant to ImmunogenX to Conduct a Clinical Trial for Latiglutenase
August 8, 2019
ImmunogenX Receives Major Grant from the National Institutes of Health (NIH) to Conduct a Clinical Trial for Latiglutenase
April 9, 2019
ImmunogenX Initiates Phase 2 Trial for its Lead Therapeutic and Diagnostic Candidates Latiglutenase and CypCel
March 14, 2019
ImmunogenX Completes CypCel Trial for Celiac Disease
September 25, 2018
AJCN Publication Garnering Tremendous Interest
March 27, 2018
NIH Awards Grant to ImmunogenX to Study Latiglutenase
October 24, 2017
Dr. Markku Mäki Joins the Scientific Advisory Board
October 12, 2017
New Latiglutenase Analyses Published in Digestive Disease & Science
August 29, 2017
Dr. Ciaran P. Kelly Joins the Scientific Advisory Board
January 4, 2017
ImmunogenX Invited to Present at the Medical Device & Investor Forum
November 17, 2016
ImmunogenX Invited to Present at the Pharmaceutical Strategy Conference
October 21, 2016
ImmunogenX Donates Patient Reported Outcome Instruments to the Foundation for Celiac Disease Outcome Measures
May 12, 2016
ImmunogenX Acquires the Assets of Alvine Pharmaceuticals
March 15, 2016
ImmunogenX has closed a Class B overscribed investment round
October 23, 2015
ImmunogenX expands its Scientific Advisory Board
September 16, 2015
Detection of gluten in probiotics
May 26, 2015
ImmunogenX signs agreement with Flamentera to acquire rights to CypCel diagnostic for celiac disease management
May 5, 2014
ImmunogenX makes key additions to its Scientific Advisory Board
May 4, 2014
ImmunogenX has completed a Series A investment round
April 22, 2014
ImmunogenX formed to develop advanced diagnostics and screening tools for celiac disease
July 14, 2013